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There is good evidence to suggest that dose intensity is important when considering the effectiveness of adjuvant chemotherapy in
patients with breast cancer. However, the development of chemotherapy-induced febrile neutropenia can lead to reduction in dose
intensity and other treatment modifications, which may negatively affect patient outcomes. Febrile neutropenia can be prevented by
the use of primary prophylactic treatment, notably with granulocyte colony-stimulating factors. This practice is supported by
international guidelines, all of which recommend that primary prophylaxis with granulocyte colony-stimulating factors should be used
with chemotherapy where the risk of febrile neutropenia is 20% or greater.
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Use of a chemotherapy regimen containing a taxane or an
anthracycline in the adjuvant treatment of patients with breast cancer
has been shown to have benefits in terms of both time to disease
progression and overall survival (Martin et al, 2005; Peto et al,2 0 0 7 ) .
However, such regimens are also associated with the potentially
serious side effects of febrile neutropenia (FN) and neutropenic sepsis
(Martin et al, 2005; Peto et al, 2007). FN is not only a major risk factor
for morbidity and mortality in patients with cancer (Aapro et al,2 0 0 6 ;
Herbst et al, 2009), but its development can also lead to a decision to
reduce the chemotherapy dose and delay subsequent treatment cycles
(Aapro et al, 2006). Such treatment modifications are a particular
concern when chemotherapy is given with curative intent (Aapro
et al, 2006), and hence the importance of FN prevention.
FN can be prevented through the prophylactic use of haemato-
poietic cell growth factors (e.g., granulocyte colony-stimulating
factors, G-CSF) – a strategy supported by current guidelines for
patients deemed to be at high risk of FN (Aapro et al, 2006; Smith
et al, 2006; Segal et al, 2008). The indications for prophylactic
administration of G-CSF are based on various risk factors,
including the degree of myelosuppression associated with the
chemotherapy regimen, and specific patient characteristics (Aapro
et al, 2006; Smith et al, 2006).
The management of serious neutropenic events is described
elsewhere in this supplement (Cameron, 2009), as is the antibiotic-
based prophylaxis of FN (Cullen and Baijal, 2009). This article
focuses on the potential consequences of modifying chemotherapy
dose density in response to FN, and the alternative approach –
primary prevention of FN through the prophylactic use of G-CSF.
FN MORBIDITY AND MORTALITY
Chemotherapy-induced neutropenia is a major risk factor for
infection-related morbidity (Aapro et al, 2006), including fungal
infections, Gram-negative sepsis, pneumonia and other lung
disease, cerebrovascular disease and disorders of the liver and
kidney (Kuderer et al, 2006).
The mortality rates associated with FN range from 2 to 21%
(Herbst et al, 2009), and the risk of death is increased by various
factors, including patient characteristics, type of malignancy,
presence of comorbidities and infectious complications (Kuderer
et al, 2006).
DOSE INTENSITY
Development of FN and neutropenic sepsis leads to significant
morbidity and mortality, and is commonly regarded as an
indication for a dose reduction or cycle delay among patients
receiving chemotherapy (Aapro et al, 2006). However, there is
evidence that such changes to chemotherapy dose intensity (DI,
dose delivered divided by the overall duration of treatment) can
have a negative effect on treatment outcomes (Wood et al, 1994;
Bonadonna et al, 1995; Leonard et al, 2003; Bonneterre et al, 2005;
Chirivella et al, 2006).
A retrospective analysis of patients undergoing adjuvant
treatment with classical 28-day CMF (cyclophosphamide, metho-
trexate and fluorouracil) showed a major survival benefit among
those who received 85% or more of the intended dose (Bonadonna
et al, 1995). Delivery of 65–85% of the planned dose was
associated with some benefit, but patients who received less than
65% fared no better than did those who received no chemotherapy
at all.
Another study compared three regimens of FAC (fluorouracil,
doxorubicin and cyclophosphamide) that differed in their DI:
moderate-DI FAC (fluorouracil 40mgm
–2 on days 1 and 8, and
doxorubicin 40mgm
–2and cyclophosphamide 400mgm
–2on day
1 for six cycles), higher-DI FAC (the same total dose as moderate-
DI FAC but delivered in just four cycles) and lower-DI FAC (half
the total dose of high-DI and moderate-DI FAC, delivered in four
cycles) (Wood et al, 1994). After 3 years, there was no difference
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significantly poorer in the lower-DI group. The authors propose
a threshold effect for chemotherapy delivery, that is, a DI below
which the benefit is significantly reduced (Wood et al, 1994).
An association between increased DI and improved outcomes
has also been reported by the French Adjuvant Study Group
(Bonneterre et al, 2005), which compared two regimens of FEC.
Patients receiving adjuvant chemotherapy for breast cancer
were given either FEC 50 (fluorouracil 500mgm
–2, epirubicin
50mgm
–2 and cyclophosphamide 500mgm
–2) or FEC 100 (as
FEC 50 but with the epirubicin dose increased to 100mgm
–2). At
10 years, there was a significant benefit in favour of FEC 100 in the
rates of disease-free survival (FEC 50, 45.3% vs FEC 100, 50.7%,
P¼0.036) and overall survival (50.0 vs 54.8%, respectively,
P¼0.038).
Looking specifically at the reduced DI brought about by dose
delay, a retrospective analysis of the records of 793 patients who
received adjuvant chemotherapy for breast cancer between 1980
and 2000 has shown that, after a median follow-up of 10 years,
patients exposed to more than two cycle delays had poorer event-
free and overall survival, compared with those whose treatment
was delivered on time (Chirivella et al, 2006). In this study,
treatment delay was defined as any cycle being delivered more
than 3 days later than planned, the whole course being completed
more than 15 days later than planned or a delivery of less than 95%
of the planned DI.
The association between the development of severe neutropenia
and reduced DI has been investigated in an audit of 422 patients
with breast cancer who received adjuvant chemotherapy (mainly
CMF or anthracycline-based) in 15 UK centres; 29% of the patients
had at least one neutropenic event (defined as hospitalisation
because of FN, a dose delay of 7 days or more because of
neutropenia, and/or a dose reduction of 15% or more because of
neutropenia), and 17% of the patients received less than 85% of the
planned total dose of their regimen (Leonard et al, 2003). Patients
who experienced a neutropenic event received a significantly lower
DI than those who did not. Around 40% of patients under-
going CMF-based chemotherapy and 32% of patients undergoing
anthracycline-based chemotherapy who experienced a neutropenic
event received less than 85% of their intended dose. Interestingly,
only 5.2% of patients in the study received haematopoietic cell
growth factors at any time during their treatment.
CHOICE OF CHEMOTHERAPY
There are many factors to consider when choosing a suitable
chemotherapy regimen for an individual patient, and little research
to show why some patients who seem suitable for a particular
regimen do not receive it. However, there are anecdotal reports
either that patients may decline effective chemotherapy or that
physicians may be unwilling to prescribe it, because of concerns
about toxicity – even when the likely side effects can be effectively
prevented or managed. For example, the findings of a survey of 50
UK oncologists, conducted in 2008, suggested that FN was a
deterrent to the prescription of docetaxel, doxorubicin and
cyclophosphamide (TAC) for patients with operable node-positive
early-stage breast cancer. Only 58% of eligible patients were
considered for the regimen, and only 32% of the eligible
population actually received it (Oncologist Breast Cancer Study,
2008). The respondents cited concern about FN as the major
barrier to prescribing TAC. Only 24% of the oncologists used
G-CSF for primary prophylaxis of FN.
Gounaris et al (2008) have shown that a patient’s age can also be
a major factor affecting the decision to use particular chemo-
therapy regimens. In their study, the mean ages of patients with
node-positive breast cancer prescribed taxane-based chemo-
therapy, anthracycline-based chemotherapy or no chemotherapy
were 52.7, 59.4 and 73.2 years, respectively. Whether age per se
should affect the choice of chemotherapy will be discussed in
detail later.
GUIDELINES ON PREVENTION OF FN
Chemotherapy dose reduction/delay is not the only strategy
available for reducing FN-related morbidity and mortality.
Another option is FN prevention through prophylactic treatment
with G-CSF, granulocyte–macrophage colony-stimulating factors
(GM–CSF) and/or antibiotics (Herbst et al, 2009).
Haematopoietic cell growth factors stimulate the proliferation
and survival of neutrophils and their precursors, and thereby
reduce the severity and duration of chemotherapy-induced
neutropenia and FN (Ozer et al, 2000; Komrokji and Lyman,
2004; Segal et al, 2008).
Indications for the primary prevention of FN through the use of
G-CSFs for patients undergoing chemotherapy have been issued by
three well-respected oncology organisations – the American
Society of Clinical Oncology (Smith et al, 2006), the European
Organization for Research and Treatment of Cancer (Aapro et al,
2006) and the National Comprehensive Cancer Network (Segal
et al, 2008). They all broadly agree that any patient with an FN risk
greater than 20% should receive primary prophylaxis with G-CSF
with each cycle of chemotherapy (Figure 1). In some instances, the
chemotherapy regimen itself carries an FN risk that exceeds this
threshold (Aapro et al, 2006). If the FN risk associated with the
regimen is 10–20%, the physician should consider whether patient
factors such as age, advanced disease or comorbidities take the
overall risk beyond 20%. If the chemotherapy regimen is
considered to present an FN risk of less than 10%, primary
prophylaxis with G-CSF should not be offered routinely – unless
there is thought to be a huge risk of serious FN complications,
such as death. However, it is highly likely that G-CSF primary
prophylaxis is not always used routinely in clinical practice,
despite these clear, evidence-based guidelines.
EVIDENCE SUPPORTING PRIMARY PROPHYLAXIS
OF FN
In a meta-analysis of 17 randomised controlled trials involving
more than 3400 patients undergoing chemotherapy, infection-
related mortality was 1.5% in those who received primary
prophylaxis with G-CSF, compared with 2.8% in controls (relative
risk (RR)¼0.055) (Kuderer et al, 2007). The rate of early
morbidity fell from 3.4% in controls to 2.7% in patients receiving
G-CSF. FN occurred once or more in 39.5% of controls and 22.4%
of G-CSF-treated patients (RR¼0.54). In 10 trials that monitored
DI, the meta-analysis found that all G-CSF recipients had a DI
higher than 90%. By contrast, DI in the control arms was lower
than 85% in six of the 10 trials.
The efficacy of pegfilgrastim, a prolonged-action pegylated form
of G-CSF, in the prevention of FN associated with chemotherapy
based on docetaxel (100mgm
–2) in breast cancer was assessed in a
study of 928 patients with metastatic breast cancer randomised to
either placebo or pegfilgrastim (Vogel et al, 2005). Compared with
the placebo group, the pegfilgrastim-treated patients had a
significantly lower rate of FN (17 vs 1%, respectively, Po0.001),
FN-related hospital admissions (14 vs 1%, Po0.001) and use of
intravenous antibiotics for the management of infections (10 vs
2%, Po0.001). During cycle 1 of chemotherapy, 11% of patients
who received placebo developed FN (i.e., two-thirds of all episodes
of FN in the placebo group), compared with 1% of pegfilgrastim
recipients. As patients who were given placebo and developed FN
were then allowed to receive pegfilgrastim during subsequent
chemotherapy cycles, the DI was not significantly different
between the two groups.
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results from the GeparTrio trial, in which patients with breast
cancer who received neoadjuvant TAC were given the following
prophylactic treatments: the antibiotic ciprofloxacin (500mg
twice daily on days 5–14), non-pegylated G-CSF (5mgkg
–1day
–1
filgrastim or 150mgm
–2day
–1 lenograstim on days 5–10),
pegfilgrastim (6mg on day 2) or a combination of the pegfilgrastim
and the ciprofloxacin schedules (von Minckwitz et al, 2008). Both
FN and grade 4 neutropenia were significantly more frequent in
patients who received either ciprofloxacin alone or non-pegylated
G-CSF, compared with those given pegfilgrastim with or without
ciprofloxacin. Indeed, no patients receiving the combination of
pegfilgrastim and ciprofloxacin developed FN during chemo-
therapy cycle 1.
The combined approach also proved beneficial in a study by
Gounaris et al (2008). In the study, patients given the complete
primary prophylaxis schedule of lenograstim (263mg subcuta-
neously on days 4–10) and ciprofloxacin (500mg twice daily on
days 5–14) had an FN rate of 0.8, and 7% needed a modification
to their chemotherapy regimen (Gounaris et al, 2008). By contrast,
when prophylaxis was inadequate (usually because G-CSF was
started later than day 5), the risk of FN was 15, and 36% of patients
required modification to their chemotherapy.
FN PROPHYLAXIS IN CLINICAL PRACTICE
Physicians need to be aware of the FN risk associated with each
regimen that they prescribe and take into account the patient-
related factors that increase that risk. Primary prophylaxis with
G-CSF should always be offered when the risk of FN is 20% or
greater. Prophylactic use of antibiotics should also be considered,
as discussed elsewhere in this supplement by Cullen and Baijal.
G-CSF treatment should start within 24–72h of the chemother-
apy dose, and be administered for long enough to allow adequate
neutrophil recovery. Treatment schedules associated with three
commonly used G-CSF formulations are summarised in Table 1.
Pegfilgrastim is administered just once per cycle, whereas shorter
acting products are used daily. The duration of use of daily G-CSF
is variable. Trial evidence has shown that FN rates are lower in
patients who receive pegfilgrastim than in those who receive
11 days of daily G-CSF (von Minckwitz et al, 2008), which suggests
that the common practice of giving daily G-CSF for 4–7 days may
provide suboptimal prophylaxis.
Risk assessment
The management of chemotherapy-induced FN is gaining increas-
ing attention as evidence accumulates to indicate that a proactive,
preventive approach may improve the delivery of care and patient
outcomes. Both chemotherapy and patient-related factors are
important when assessing which chemotherapy regimen and
supportive treatments to give to a particular patient.
The risks associated with both the prescribed chemotherapy
regimen and patient factors (Figure 1) must be assessed before
commencing chemotherapy and before delivering each subsequent
cycle (Aapro et al, 2006).
The choice of chemotherapy is generally the main risk factor for
FN, and if two different regimens are believed to offer equal
efficacy to the patient, the regimen with the lower risk of FN should
be chosen. However, looking specifically at patients with breast
cancer, it is well documented that taxane-containing regimens are
significantly more effective than those without taxanes (Peto et al,
2007), at the cost of increased FN rates (Bria et al, 2005).
Several patient risk factors are associated with development of
FN. There is evidence from well-designed trials showing that FN is
Table 1 G-CSF treatment schedules
Formulation Route Dose Frequency Duration
Lenograstim Subcutaneous 150mgm
–2 Daily 28 consecutive
days
Filgrastim Subcutaneous 5mgkg
–1 Daily Up to 38 days
Pegfilgrastim Subcutaneous 6mg
–1 Once per
cycle
Once per cycle
Assess risk of FN for
planned chemotherapy 
regimen
      Patients receiving
     curative chemotherapy 
     (e.g. TAC) would be 
     considered at high 
     risk of FN 
FN risk > 20%
(high)
FN risk 10– 20%
(medium)
FN risk <10%
(low)
Prophylactic G-CSF 
use recommended
G-CSF use 
not indicated
Overall FN risk > 20%
Overall FN risk <20%
      Age >65 years
      Previous episode of FN
     Advanced disease
      Serious co-morbidities
      Poor performance status
      Cytopenias due to tumour bone 
     marrow involvement
      Female gender
      Haemoglobin <12 g dl–1
      Poor nutritional status
      Combined chemotherapy
     Open wounds/active infections
Assess other factors that may affect FN risk
Figure 1 Algorithm for FN prevention in patients receiving chemotherapy, based on guidelines by the European Organization for Research and
Treatment of Cancer (Aapro et al, 2006) and the American Society of Clinical Oncology (Smith et al, 2006).
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those with advanced disease, a previous history of FN and low
performance status (Aapro et al, 2006). There is also evidence
suggesting other FN risk factors, including female sex, haemo-
globin below 12gdl
–1, cardiovascular disease, renal disease and
abnormal liver function tests, in particular raised bilirubin (Aapro
et al, 2006; Lyman et al, 2007). Careful assessment of all the
treatment and patient factors should be formulated, and the
guidelines closely adhered to.
Elderly patients
Elderly patients account for only a small proportion of the
population with early-stage breast cancer (prevalence approa-
ching 7% among the over-70s) (Louwman et al, 2007). This group
is worth mentioning, however, as elderly patients present parti-
cular challenges, including reduced tolerance to chemotherapy
(Wedding et al, 2007) and greater susceptibility to the develop-
ment of FN (Lyman and Dale, 2003). Importantly, with careful
patient selection, chemotherapy can be effective and tolerable in
older as well as younger individuals.
It is important to note that chronological age, by itself, is not a
reliable indicator of life expectancy, functional reserve or the risk
of treatment complications (Wedding et al, 2007). Elderly patients
require a comprehensive geriatric assessment, looking at function,
comorbidities, nutritional status, cognition, emotional evaluation
and socioeconomic issues (Wedding et al, 2007).
A systematic review of the literature has provided evidence to
support the use of haematopoietic growth factors in elderly people,
to reduce the risk of neutropenic events and the need for reduced
DI (Lyman and Dale, 2003), but specific evidence for the benefits of
primary prophylaxis of FN in elderly breast cancer patients is
currently lacking. Further studies are needed.
ROLE OF SECONDARY PROPHYLAXIS WITH G-CSF
Patients with a high risk of FN (over 20%) should be offered
primary prophylaxis with G-CSF, in accordance with guidelines
(Aapro et al, 2006; Smith et al, 2006; Segal et al, 2008). However, a
predicted low risk (under 10%) of FN is no guarantee that the side
effect will not occur. Secondary prophylaxis during subsequent
cycles is therefore an option if a low-risk patient develops FN
during chemotherapy.
There are no prospective studies of the value of secondary
G-CSF prophylaxis (Hupperets and Tjan-Heijnen, 2006). After
patients in a pivotal G-CSF trial were allowed to switch from
placebo to G-CSF if they developed FN in the first cycle (Crawford
et al, 1991), the FN rate fell from 100% in cycle 1 to 23% in cycle 2.
However, definite conclusions on the efficacy of secondary
prophylaxis cannot be drawn from these observations because
many trials report a decline in the incidence of FN in later cycles
without administering prophylaxis (Hupperets and Tjan-Heijnen,
2006).
Secondary prophylaxis should be offered if a patient develops
FN, despite being in a low FN risk category, and it is judged
important to maintain their DI. However, dose reduction or delay
may be appropriate for some patients such as, for example, those
receiving palliative chemotherapy and those who develop grade 3/4
non-haematological toxicities that cannot be attributable to FN. If
a patient is likely to develop a serious complication resulting from
FN, such as death, then primary prophylaxis should be considered.
CONCLUSION
As well as being associated with morbidity and mortality (Aapro
et al, 2006; Kuderer et al, 2006), chemotherapy-induced FN can
also lead to treatment modifications and poorer outcomes for
patients – a particular concern when chemotherapy is being given
with curative intent (Aapro et al, 2006). However, primary
prophylaxis of FN, using G-CSF, can reduce the risk of FN
developing in the first place (Aapro et al, 2006; Smith et al, 2006;
Segal et al, 2008). Regimen-based and patient-based indications for
its use are set out in international guidelines (Aapro et al, 2006;
Smith et al, 2006; Segal et al, 2008). Patients whose risk of
chemotherapy-induced FN is 20% or greater should be given
primary prophylactic G-CSF. If a patient develops FN during a less
intensive regimen, and DI needs to be maintained, secondary
prophylactic G-CSF should be strongly considered for the support
of subsequent treatment cycles.
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